Cl[CH2:2][C:3]([NH2:5])=[O:4].[CH:6]([N:9]1[CH2:14][CH2:13][CH:12]([NH:15][S:16]([CH2:19][CH2:20][NH:21][C:22]([C:24]2[S:25][C:26]([Cl:29])=[CH:27][CH:28]=2)=[O:23])(=[O:18])=[O:17])[CH2:11][CH2:10]1)([CH3:8])[CH3:7]>>[C:3]([CH2:2][N:15]([CH:12]1[CH2:13][CH2:14][N:9]([CH:6]([CH3:8])[CH3:7])[CH2:10][CH2:11]1)[S:16]([CH2:19][CH2:20][NH:21][C:22]([C:24]1[S:25][C:26]([Cl:29])=[CH:27][CH:28]=1)=[O:23])(=[O:17])=[O:18])(=[O:4])[NH2:5]5-Chloro-thiophene-2-carboxylic acid {2-[carbamoylmethyl-(1-isopropyl-piperidin-4-yl)-sulfamoyl]-ethyl}-amide was prepared by an analogous procedure as described in example 15 starting from 48 mg (2 equiv.) 2-chloro-acetamide and 100 mg (0.25 mmol) 5-chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide. Final purification by preparative RP-HPLC (CH3CN/H2O gradient+0.1% TFA) gave pure 5-chloro-thiophene-2-carboxylic acid {2-[carbamoylmethyl-(1-isopropyl-piperidin-4-yl)-sulfamoyl]-ethyl}-amide. The title compound was obtained as its trifluoroacetate in form of a colorless amorphous material.
読み込み中…